

(19)



(11)

EP 3 456 333 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:

A61K 31/7088 ^(2006.01) **A61K 31/7125** ^(2006.01)
A61P 35/00 ^(2006.01) **A61P 35/02** ^(2006.01)
A61P 7/00 ^(2006.01) **A61P 7/06** ^(2006.01)

(48) Corrigendum issued on:

13.05.2020 Bulletin 2020/20

(45) Date of publication and mention
of the grant of the patent:

01.04.2020 Bulletin 2020/14

(21) Application number: **18196690.4**

(22) Date of filing: **15.11.2013**

(54) **USE OF THE TELOMERASE INHIBITOR IMETELSTAT FOR THE TREATMENT OF MYELOYDYSPLASTIC SYNDROME**

VERWENDUNG VOM TELOMERASE-HEMMER IMETELSTAT ZUR BEHANDLUNG DES MYELOYDYSPLASTISCHEN SYNDROMS

UTILISATION DE L'INHIBITEUR DE LA TÉLOMÉRASE IMETELSTAT POUR LE TRAITEMENT DU SYNDROME MYÉLODYSPLASIQUE

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

Designated Extension States:

BA ME

(30) Priority: **07.12.2012 US 201261734941 P**

15.03.2013 US 201361799069 P

15.03.2013 US 201313841711

05.11.2013 US 201361900347 P

(43) Date of publication of application:

20.03.2019 Bulletin 2019/12

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:

13861008.4 / 2 928 477

(73) Proprietor: **Geron Corporation**
Foster City, CA 94404 (US)

(72) Inventors:

- **STUART, Monic, J.**
Hillsborough, CA 94010 (US)
- **KELSEY, Stephen**
Palo Alto, CA 94301 (US)

(74) Representative: **Bassil, Nicholas Charles**

Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL (GB)

(56) References cited:

CN-A- 101 220 044 US-A1- 2005 282 893

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 456 333 B8

- GABRIELA M BAERLOCHER ET AL: "Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results", ANNUAL MEETING OF THE AM SOCIETY, vol. 120, no. 21, 16 November 2012 (2012-11-16), pages 1-16, XP055254428,
- KAKIUCHI YASUTAKA ET AL: "Inhibition of Human Tumor Cell Proliferation by the Telomerase Inhibitor TELIN", CYTOLOGIA (TOKYO), vol. 75, no. 2, June 2010 (2010-06), pages 177-183, XP008180568, ISSN: 0011-4545
- TAUCHI TETSUZO ET AL: "Activity of a novel G-quadruplex-interactive telomerase inhibitor, SOT-095, against human leukemia cells: Involvement of ATM-dependent DNA damage response pathways", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US , vol. 102, no. 11 16 November 2003 (2003-11-16), page 652a, XP008180575, ISSN: 0006-4971 Retrieved from the Internet: URL:<http://www.bloodjournal.org/>
- BAERLOCHER GABRIELA M ET AL: "Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US , vol. 120, no. 21 1 November 2012 (2012-11-01), page 179, XP008180577, ISSN: 0006-4971 Retrieved from the Internet: URL:<http://www.bloodjournal.org/>
- CLAUDIO BRUNOLD ET AL: "3843: Imetelstat, A Potent Telomerase Inhibitor, Inhibits the Spontaneous Growth of CFU-Meg In Vitro From Essential Thrombocythemia Patients but Not From Healthy Individuals", BLOOD, vol. 118, no. 21, 18 November 2011 (2011-11-18), - 13 December 2011 (2011-12-13), page 3843, XP055254840, US ISSN: 0006-4971
- CATENACCI ET AL: "Myelodysplastic syndromes: A comprehensive review", BLOOD REVIEWS, CHURCHILL LIVINGSTONE, AMSTERDAM, NL, vol. 19, no. 6, 1 November 2005 (2005-11-01), pages 301-319, XP005167052, ISSN: 0268-960X, DOI: 10.1016/J.BLRE.2005.01.004
- FENAUX ET AL (POSTER 4256) ASH (2017): POSTER, 2017,
- STEENSMA ET AL (ABSTRACT 463) ASH (2018): ASH ORAL PRESENTATION, 2018,
- STEENSMA ET AL (ABSTRACT S1557) EHA (2018): EUROPEAN HEMATOLOGY ASSOCIATION, 2018,